By themselves, analyst upgrades should be viewed as one-off events. But when you combine them with other factors, you can understand why these stocks may belong on your watchlist.  

Analyst Upgrades Are a Signal That Filters Out Noise 

Forty years ago, many would-be investors shied away from picking individual stocks because there wasn’t a lot of information, and getting to it was time-consuming. In many cases, the juice wasn’t worth the squeeze.  

Ironically, today, many investors avoid picking individual stocks because, with a firehose of data available to them and just a click away, they struggle with analysis paralysis. There are too many names to choose from; too many opportunities to chase.

It can get noisy. Analyst upgrades are one way to quiet that noise. Analysts work for banks, hedge funds, and other institutional investors, and have access to information about companies that retail investors do not. That doesn’t mean they can’t make mistakes, but it does mean that retail investors should pay attention to their analysis, particularly when they forecast a price well above the current price. 

When you’re looking to find the right stocks among the thousands to choose from, analyst upgrades can be a signal that points you to profitable opportunities. 

Rocket Lab (RKLB): Launch Momentum and Analyst Optimism Build Ahead of Earnings

Rocket Lab (NASDAQ: RKLB) is one of the most popular stocks in the emerging space sector. In the last 12 months, RKLB stock is up more than 300%. The company had a record year of launches of its Electron rocket, and as of its last earnings report, it already has a record backlog in place for 2026.  

This will also be the year that the company begins launching its Neutron rockets, which can house larger payloads. Rocket Lab also has a growing Space Systems business, which includes spacecraft being designed for NASA’s planned Mars missions. 

As of Jan. 19, RKLB stock is trading about 33% above its consensus price target. However, on Jan. 16, the stock received a bullish upgrade from Morgan Stanley, which moved the stock from Equal Weight to Overweight and increased its price target to $105 from $67. That’s only about 10% above the current RKLB stock price, which suggests that there could be more downside risk before earnings. Opportunistic investors should use that as a dip to buy.  

Grab (GRAB): Improving Profitability and AI Expansion Drive Bullish Sentiment

Grab Holdings Inc. (NASDAQ: GRAB) is the parent company of a “super app” for consumers across Southeast Asia. The company’s offerings encompass ride-hailing, food and package delivery, and digital payments.  

Grab’s revenue has been growing strongly year-over-year and that trend is expected to continue in the next four quarters. The company has also delivered four consecutive quarters of positive earnings per share (EPS). That’s another trend that’s expected to increase in the next twelve months.  

One reason to believe in that growth may come from Grab’s acquisition of the Chinese company, Infermove. This will allow the company to deploy AI-powered Carri robots in the first mile and last mile of the delivery process. Analysts believe last-mile robotics delivery could be a $20 billion opportunity by 2027.  

Like many emerging market stocks, GRAB stock doesn’t draw as much analyst attention. However, the sentiment has been bullish over the last three months, including a bullish upgrade from Hold to Buy from HSBC. This increase in analyst sentiment has pushed the stock’s consensus price target to $6.58, which would represent a 50% upside from the stock’s current level.  

BioNTech (BNTX): Oncology Pipeline Progress Sparks Wall Street Upgrade

BioNTech (NASDAQ: BNTX) is part of the biotechnology sector. The German-based company is known for developing next-generation immuotherapies and vaccines. The company burst into the minds of mainstream investors when it partnered with Pfizer Inc. (NYSE: PFE) on its Comimaty vaccine for Covid-19.  

However, analysts are bullish on the stock because of the strides that the company has made with its oncology portfolio. The company’s pipeline includes drug candidates in late-stage clinical trials, including immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies.  

BioNTech expects data readouts from seven late-stage trials this year and expects to apply to the U.S. Food and Drug Administration (FDA) for approval of one of its drug candidates. Although the company won’t realize any revenue in 2026, it hopes to have multiple revenue-producing candidates in market by 2030.  

On Jan. 16, Goldman Sachs upgraded BNTX stock from Neutral to Buy and raised its price target to $142 from $115. Importantly, that price target is above the $140 consensus price, which itself is over 28% higher than the stock’s closing price on Jan. 16. 

A Final Word on Analyst Upgrades 

As is the case with many things in life, there’s strength in numbers. A single analyst upgrade may not carry that much weight. But when there’s one; there are usually more. And even those analysts don’t upgrade the stock; they may reiterate a rating of Buy or its equivalent and raise their price target. That’s still a bullish signal for investors because it suggests the stock price is likely to move higher.  

However, one important consideration is timing. In many cases, an analyst’s price target is for 12 to 18 months in the future. That makes them less helpful for momentum investors, but it could be an option for swing traders who are looking to take a long position (i.e., holding the stock for more than a year).  

It’s easy to see why. Many analysts forecast the global space economy to be a $1 trillion market by 2030. Growth in this sector is being propelled by falling launch costs, explosive demand for satellite applications, and a healthy case of FOMO (fear of missing out) from retail investors. 

To be fair, space stocks have been profitable investments. Many of these stocks have generated returns of over 100% in the last year. However, many of these companies are not profitable, and that means that valuations are stretched, to say the least. 

That doesn’t mean they’re poor investments, but many of these stocks are still in the speculative stage. And as many investors know, investing in speculative stocks is like a game of musical chairs. You don’t know when the music will stop, but you don’t want to be the one without a chair when it does. 

This article focuses on three stocks in this emerging sector. Two of them have been among the top-performing stocks in the entire market. The other has been a laggard but has shown recent signs of a turnaround.

Once again, this isn’t a sector to avoid. The growth is real and backed up by real contracts. But stock prices can get ahead of the story, and in this case, the fundamentals. That makes managing your positions critical. 

Rocket Lab: The Current King of Space Stocks

Rocket Lab USA Inc. (NASDAQ: RKLB) is one of the top names among space stocks. RKLB stock is up 154% in the last 12 months. The company’s launch business is driving the business, as its Electron rockets are now on a regular schedule. Analysts are optimistic about the future demand for the company’s Neutron rockets, which can deliver larger payloads and will compete with the SpaceX Falcon 9. 

However, the passionate band of Rocket Lab investors quickly points out that the company has a growing services business. This will position the company as an end-to-end solution in this growing industry. 

Revenue is increasing, but Rocket Lab isn’t profitable, and it’s not expected to be profitable until 2027 at the earliest. That puts the focus on the company’s lofty price-to-sales (P/S) ratio of over 71x. Plus, from a technical standpoint, RKLB stock is trading at or slightly below oversold territory based on its relative strength indicator (RSI).

Investors should also note that short interest in RKLB stock is around 13%. That’s not aggressively high, but it suggests that much of the good news is priced in. Retail investors may find that the all-time high the stock made in August may serve as resistance without a new catalyst. Analysts are raising their price targets, but it’s likely that the stock will need to take a breather before it makes a run to new highs. 

AST SpaceMobile: On Track to Connect the World

Communications services are a key driver of satellite launches. That’s the bull case for AST SpaceMobile Inc. (NASDAQ: ASTS). The company is developing the first and only end-to-end space-based cellular broadband network that connects directly to standard mobile phones. The stock is up 103% in the 30 days ending October 17 after the company signed a deal with Verizon Communications.

Starting in 2026, Verizon will be able to use AST SpaceMobile’s network of low-Earth orbit satellites to deliver space-based, direct-to-cellular services to its customers. It’s hard to overstate what this means for AST SpaceMobile’s topline growth in the coming years. 

However, the recent surge in the stock has priced in all of that growth, and more. It’s also important to point out that, like Rocket Lab, the company isn’t going to be profitable in the near term. 

ASTS stock is trading about 45% above its consensus price target. Short interest over 20% combined with a relative strength indicator near overbought levels suggests a pullback is in store. 

The bull case for ASTS stock is in place, but the technicals are outrunning the fundamentals at the moment. Put this on a watchlist and identify a price target at which you’d be interested in owning the stock. 

Intuitive Machines: A Grounded Entry Among Space Stocks

Intuitive Machines (NASDAQ: LUNR) made headlines for its probe that landed on the moon’s surface. LUNR stock popped on that news in early 2025, but the stock has come back to earth and was down 33?% year-to-date as of October 17. 
The company is generating, albeit not necessarily growing, revenue and in a familiar theme is not profitable.. However, the company is broadening its portfolio to include satellite production which is likely to broaden the company’s revenue base over time.

Like many companies, Intuitive Machines success or failure will come down to performance. If it’s able to execute, the opportunity will be measured in decades. On a positive note, the company is not strapped for cash, but its growth may rely on factors that are outside its control. 

That said, LUNR stock is currently trading about 26% below its consensus price and has a neutral relative strength index. Analysts have mixed opinions on the stock, which can make it tricky for retail investors to time their entry. Adding to the complexity, short interest is above 27%, which could also keep pressure on the stock in the short term.